Department of Medicine, University of Toronto.
Division of Infectious Diseases.
AIDS. 2020 Mar 1;34(3):433-437. doi: 10.1097/QAD.0000000000002441.
HIV preexposure prophylaxis and postexposure prophylaxis are two major biomedical HIV prevention modalities. The utility of these prevention tools for individuals with infrequent high-risk HIV exposures remains uncertain. HIV postexposure prophylaxis-in-pocket ('PIP') may be an effective HIV prevention tool in such situations. Here, we present long-term follow-up of a cohort of patients initiated on PIP for HIV prevention.
We retrospectively evaluated clinical characteristics of patients initiated on PIP as a primary HIV prevention tool between 1 January 2016 to 31 May 2019 at the Toronto General Hospital HIV Prevention Clinic and St. Michael's Hospital HIV Clinic, both in Toronto, Canada. Patients were referred for consideration of a biomedical HIV prevention modality. Individuals with a low frequency of high-risk exposures to HIV were initiated on PIP after counselling, and were followed at regular intervals. Demographic and clinical data was collected with a standardized form.
In total, 79 patients were initiated on PIP as a primary HIV prevention modality and followed for a mean duration of 14.8 months combining for a total of 97.3 patient-years. Twenty-one (26.6%) patients used their PIP, and 32 courses of PIP were taken during the study period. Transitions between HIV prevention modalities included 13 (16.5%) patients who transitioned from PrEP to PIP, and 22 (27.8%) patients who transitioned from PIP to PrEP. No HIV seroconversions were detected during the course of this study.
PIP is helpful HIV prevention modality for individuals with a low frequency of high-risk HIV exposures.
HIV 暴露前预防和暴露后预防是两种主要的生物医学 HIV 预防手段。对于偶发高危 HIV 暴露的个体，这些预防工具的效用仍不确定。HIV 暴露后预防随身包（“PIP”）在这种情况下可能是一种有效的 HIV 预防工具。在此，我们报告了一组接受 PIP 预防 HIV 的患者的长期随访结果。
我们回顾性评估了 2016 年 1 月 1 日至 2019 年 5 月 31 日期间在加拿大多伦多总医院 HIV 预防诊所和圣迈克尔医院 HIV 诊所接受 PIP 作为主要 HIV 预防手段的患者的临床特征。这些患者是因考虑使用生物医学 HIV 预防方法而被转介。经咨询后，偶发高危 HIV 暴露的个体接受 PIP 治疗，并定期随访。收集了人口统计学和临床数据，并采用标准化表格记录。
共有 79 名患者接受 PIP 作为主要 HIV 预防手段，随访时间平均为 14.8 个月，总共有 97.3 人年。21 名（26.6%）患者使用了 PIP，在研究期间共服用了 32 个疗程的 PIP。HIV 预防方式的转变包括 13 名（16.5%）从 PrEP 转为 PIP 的患者和 22 名（27.8%）从 PIP 转为 PrEP 的患者。在本研究期间未检测到 HIV 血清转换。
PIP 是一种有助于偶发高危 HIV 暴露个体的 HIV 预防手段。
